Genmab — Februar 2021
-
The share is getting closer to its long-term support in weekly data, at DKK 1913.5, which offers good timing for buyers.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The group usually releases upbeat results with huge surprise rates.
Over the last twelve months, the sales forecast has been frequently revised upwards. -
Credit Suisse 2235
DNB Markets 2250
Handelsbanken (SHB) 2400
BoA-Merrill Lynch 2415
Bernstein 2500
Kempen 2500
Morgan Stanley 2532
Suntrust Robinson 2555
Barclays 2600
UBS 2630
Guggenhein Securities 2648
Danske Bank 2678
Jyske 2700
Nykredit 2700
Ø. Ugebrev 2700
Jefferies 2800
RBC Capital Markets 2815
Truist Securities 2858
Citigroup 3000
H.C. Wainright 3014 -
Så kan man jo altid diskutere om et 7 md. gl kursmål er gammelt eller ej. Jeg synes ikke de giver så meget mening i vor hastige nutid, hvis et kursmål kun opdateres et par gange om året. I var nogle stykker der talte om det herinde for nylig.. og et af synspunkterne var at man kun burde indregne kursmål mindre end 4 (eller var det 6) md gamle.
-
Passer præcist med mine tal dårligere i debatten. Ingen anbefaling, men selv ser jeg Genmabaktien som klart købsmoden. Det er - for mig udelukkende en skæven til TA der afgør tidspunkt. Købte/supplerede igår vil jeg tilføje, men aner ikke om vi har bundet.
-
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind